sagerx.com (SAGE) - Long-Term Liabilities to Capital

Sage Therapeutics, Inc. (SAGE) is an innovative developer of drugs for the therapy of CNS disorders. This price chart demonstrates the company's potential in creating neuroactive drugs, where the indicator stands at 0.03. The business currently relies on the sales of a single product while cutting costs following the failure of other molecules. Meanwhile, risk is amplified by aggressive pressure from industry behemoths seeking to push the company out of the market with affordable analogs.

For Sage Therapeutics, Inc. (SAGE), the development of neurobiological drugs requires significant funding until they achieve full recognition by insurance plans. This metric compares the volume of long-term loans to total equity, determining the business's degree of dependence on borrowed funds. By analyzing the share of long-term liabilities in equity, an investor assesses the resilience of the financing structure to changes in Fed rates. A high ratio signals risks if the pace of drug commercialization slows. This allows for a comprehensive assessment of the company's financial autonomy.